Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF-transduced allogeneic prostate cancer cells

Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF-transduced allogeneic prostate cancer cells

Previous vaccination studies in patients with castration-resistant prostate cancer (CRPC) showed improved survival without prolongation of progression-free survival (PFS). This might be explained by enhanced efficacy of subsequent therapies because of heightened immune status. We therefore evaluated...

Full description

Saved in:
Bibliographic Details
Main Authors: Joyce M. van Dodewaard-de Jong, Saskia JAM Santegoets, Peter M. van de Ven, Jurjen Versluis, Henk M. W. Verheul, Tanja D. de Gruijl, Winald R. Gerritsen, Alfons J. M. van den Eertwegh
Format: Article
Language:English
Published: Taylor & Francis Group 2016-04-01
Series:OncoImmunology
Subjects:
Cancer vaccines
chemotherapy
docetaxel
GVAX
immunotherapy
mitoxantrone
Online Access:https://www.tandfonline.com/doi/10.1080/2162402X.2015.1105431
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/2162402X.2015.1105431

Similar Items